Table 3. Univariate and multivariate analysis for PFS.
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Treatment regimen | |||||
| mFOLFIRINOX vs. GEMOX | 0.499 (0.266–0.937) | 0.031 | 0.459 (0.241–0.873) | 0.018 | |
| Age | |||||
| ≥60 vs. <60 | 1.157 (0.616–2.174) | 0.650 | 1.189 (0.607–2.328) | 0.614 | |
| Sex | |||||
| Male vs. female | 0.474 (0.231–0.972) | 0.042 | 0.381 (0.172–0.843) | 0.017 | |
| ECOG | |||||
| 1 vs. 0 | 1.160 (0.606–2.221) | 0.655 | 1.256 (0.592–2.666) | 0.553 | |
| Disease status | |||||
| Metastatic vs. locally advanced | 2.317 (1.170–4.587) | 0.016 | 2.703(1.269–5.754) | 0.010 | |
| CA 19-9 | |||||
| ≥37 vs. <37 | 1.323 (0.663–2.642) | 0.427 | 0.650 (0.280–1.513) | 0.318 | |
P<0.05 was considered statistically significant. PFS, progression-free survival; HR, hazard ratio; ECOG, Eastern Cooperative Oncology Group.